AdaptHealth AHCO
- Market cap
- $820.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- 21.0×
- Revenue, 12 months
- $3.2B
- +4% on a year ago
- Net margin
- −7.1%
- Free cash flow yield
- 11.9%
AdaptHealth trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $3.2B over the last twelve months, up 4% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $804M+6% | $858.2M+10% | $792.5M+6% | $806M+2% | $805.9M+0% | $856.6M−0% | $777.9M−2% | $657.1M−19% | $820.3M+2% | $846.3M−1% | $819.8M+5% | $740.3M+13% | |
| Cost of revenue | $693.5M+7% | $698.3M−0% | $635M−3% | $636.6M−6% | $643.8M−7% | $664.4M−5% | $657.4M+4% | $521.3M−18% | $658.4M+2% | $674.1M+2% | $708.3M+8% | $636.1M+22% |
| Gross profit | $110.5M+1% | $159.9M+98% | $157.5M+77% | $169.4M+41% | $162.1M+47% | $192.2M+20% | $120.4M−24% | $135.8M−20% | $161.9M−0% | $172.2M−10% | $111.5M−7% | $104.2M−23% |
| SG&A | $45.2M+11% | $47.3M+26% | $89M+87% | $99.4M+98% | $87.3M+93% | $83.5M+77% | $86.9M−3% | $95.3M−4% | $90.1M+3% | $107.9M+29% | $95.9M+10% | $96.1M+1% |
| −$461M | −$217.8M | $50.5M+93% | $52M−4% | $63.5M | $97.7M | $23.2M−54% | $65.7M+26% | $61.7M−3% | −$73.3M | $5.5M−76% | −$137.8M | |
| Interest expense | $32.3M+13% | $34.2M+12% | $32.5M+2% | $33M+2% | $31.4M−3% | $27.8M−19% | $28.4M−13% | $27.5M−17% | $25.4M−19% | $22.3M−20% | $25.6M−10% | $26.2M−5% |
| Pre-tax income | −$487.5M | −$271.7M | $5.5M−63% | $27.8M+36% | $32M | $70.7M | −$5.2M | $38.2M+37% | $36.4M+14% | −$98M | −$20.1M+285% | −$165.3M |
| −$34.6M | −$18.1M | $6.6M | $7.2M+34% | $8.1M | $19.3M | $850K−87% | $32.8M+352% | $10.6M+31% | $3.5M−82% | −$5.2M | −$21.2M | |
| Net income | −$454.1M | −$254.5M+9734% | −$2.1M | $19.4M+39% | $22.9M | $50.3M | −$7.2M+238% | $14.7M−25% | $24.5M+7% | −$102.8M | −$16M+123% | −$133.9M |
| −$3.43 | −$1.91+9450% | −$0.02−67% | $0.13+44% | $0.15 | $0.34 | −$0.05+150% | $0.10−23% | $0.16+7% | −$0.74 | −$0.12+140% | −$0.99 | |
| 135M−2% | 133M−1% | 132.9M−2% | 136M−0% | 136.5M+1% | 135.8M+2% | 134.8M+1% | 137.1M+1% | 137.2M+1% | 135.4M−0% | 135.8M+1% | 136.1M−1% |
Gross profit: 30 periods, Q1 FY19 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21 and Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest AdaptHealth's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AHCOAdaptHealth | $820.8M | n/m | 37.2× | 0.3× | +4% | −7.1% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| Peer median | $1.6B | 24.8× | 29.2× | 1.4× | +8% | 5.4% |
Investors who own it
Investors we follow who held AdaptHealth at the end of Jun 30, 2026, from their 13F filings.
- Reinhart PartnersReinhart Partners1.8% of portfoliotrimmed
More on AdaptHealth
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #5of 45Hospital and care facility stocks with the lowest price to sales ratio
- #6of 32Hospital and care facility stocks with the highest free cash flow yield
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .